In a report released today, Tim Anderson from Bank of America Securities reiterated a Sell rating on Amgen (AMGN – Research Report), with a ...
Amgen Inc . (NASDAQ:AMGN), a leading biotechnology company with a market capitalization of $151.3 billion, is navigating a ...
Zacks.com on MSN1d
Amgen Set to Report Q4 Earnings: Is a Beat in the Cards?We expect Amgen AMGN to beat expectations when it reports fourth-quarter and full-year 2024 results on Feb. 4, after market ...
Amgen Inc. closed 18.42% short of its 52-week high of $346.85, which the company achieved on July 25th.
As Sandoz gears up to launch one of the most anticipated biosimilars of the year, the company could face near-term ...
This December, Amgen received a second state incentive to expand its Holly Springs operations by adding another drug ...
Amgen Inc (AMGN) stock saw a decline, ending the day at $280.3 which represents a decrease of $-2.65 or -0.94% from the prior close of $282.95. The stock opened at $280.13 and touched a low of $279.97 ...
Today, Benzinga 's options scanner spotted 28 uncommon options trades for Amgen. This isn't normal. The overall sentiment of ...
On January 23, 2025, the District Court for the District of New Jersey entered a Consent Judgment and Injunction in view of a ...
Citi lowered the firm’s price target on Amgen (AMGN) to $295 from $310 and keeps a Neutral rating on the shares. Ahead of the Q4 earnings, the ...
North Carolina achieved a record-breaking year for life sciences investments in 2024. Twenty-five companies announced ...
Amgen executives and employees, local and state elected dignitaries, and an assortment of other local economic development ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback